project: cardiodx

CardioDX logo

Connect with a Sales Specialist



The COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) Study


To validate the Corus CAD test in an independent cohort of patients who had been referred for myocardial perfusion imaging (MPI), but who had not yet been referred for invasive coronary angiography. This population of patients more closely resembles the intended use population for the Corus CAD test than that observed in the PREDICT study.




431 samples analyzed from 19 sites in the U.S.

Study Design:

COMPASS1 enrolled nondiabetic symptomatic patients who had been referred to MPI by their physician. If the MPI was positive and it was clinically indicated, the patient had an invasive coronary angiography. If the MPI was negative, the patient was referred to research coronary computed tomography angiography (CCTA) to assess what level of coronary disease, if any, was present. The investigators were blinded to the Corus CAD results. Investigators compared the ability of a Corus CAD score at a pre-defined threshold of 15 and MPI to accurately determine case-control status measured by invasive coronary angiography or CCTA.

Key Findings:

The COMPASS study found that the Corus CAD algorithm demonstrated a sensitivity of 89% and a negative predictive value (NPV) of 96% at the pre-specified threshold of 15 in a population of symptomatic men and women referred to MPI for the evaluation of obstructive CAD.


Published online, Circulation: Cardiovascular Genetics (April 2013)2



  1. COMPASS Study. Clinical trial summary found at:, NCT01117506.
  2. Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet. 2013;6(2):154-162.